Drug Trial Radar · NCT06656494
ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
266
Planned (sponsor's estimate)
Start
Dec 18, 2024
Primary completion
Jun 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ICP-248 in combination with azacitidine in patients with acute myelogenous leukemia and Myelodysplastic Syndromes.
Conditions
- Acute Myelogenous Leukemia
- Myelodysplastic Syndromes (MDS)
Interventions
ICP-248Drug
Eligible patients will receive ICP-248 orally as per the protocol,once daily for every 28 days as one treatment cycle
AzacitidineDrug
Eligible patients will receive azacitidine subcutaneously or intravenously as per the protocol,once daily on days 1-7 of each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence, type, and severity of dose-limiting toxicity (DLT).Time frame: 2.5 years
- Recommended phase II dose (RP2D) and/or maximum tolerated dose (MTD).Time frame: 2.5 years
- The incidence, nature, and severity of adverse events (AEs) as assessed per National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) criteria.Time frame: 2.5 years
- AML cohort:Composite complete remission rate by Investigator per ELN 2017 criteria.Time frame: 2.5 years
- AML cohort:Composite complete remission rate by completion of cycle 2 by Investigator per ELN 2017 criteria.Time frame: 2.5 years
- MDS cohort:mOR rate, including CR, mCR, and PR, assessed by Investigator at any time point during the study per revised IWG 2006 MDS Criteria.Time frame: 2.5 years
Locations
22 sites in 3 countries. Site status is shown where the registry gives one.
Chao Family Comprehensive Cancer Center, University of California, Irvine
Orange, California · Recruiting
Yale University, Yale Cancer Center
New Haven, Connecticut · Recruiting
H Lee Moffitt Cancer Center & Research Institute
Tampa, Florida · Recruiting
NYU Langone Health
New York, New York · Recruiting
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina · Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
St Vincent's Hospital
Sydney, New South Wales, Australia · Recruiting
Royal Perth Hospital
Perth, Western Australia, Australia · Recruiting
Anhui Provincial Hospita
Hefei, Anhui, China · Recruiting
Peking University People's Hospital
Beijing, Beijing Municipality, China · Recruiting
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Recruiting
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China · Recruiting
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shengjing Hospital of China Medical University
Shengyang, Liaoning, China · Recruiting
Sichuan Provincial People's Hospital
Chengdu, Sichuan, China · Recruiting
Tianjin People's Hospital
Tianjin, Tianjin Municipality, China · Recruiting
The First Affiliated Hospital, Zhejiang University School of Medicine
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.